Switching between GLP-1 drugs: what the evidence says

What did @maicyrobison actually say?

At week 23, @maicyrobison reports losing 47 pounds on tirzepatide after previously losing 52 pounds over 4.5 months on semaglutide. Her core argument is that going slower on dose increases made this round noticeably better: fewer side effects, less nausea, less GI trouble. She says she stayed at 5.5 mg tirzepatide for six straight weeks, losing one to two pounds per week, and credits the improved experience to patience and higher protein intake rather than any inherent superiority of one drug over another. She also tells her audience to stop comparing their results to others and to accept that slower loss is still real progress.

She's careful to note she works with a provider and specifically says, "you need to talk to your provider before doing anything." That disclaimer matters, and she means it rather than just tacking it on at the end.

Does the science back this up?

On dose escalation and side effects: yes, there's legitimate support here. The evidence is not airtight, but it points in her direction. Gradual titration is the standard clinical approach for a reason.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) used a structured 20-week escalation for tirzepatide, and GI adverse events were still the most common reason for discontinuation. But faster titration does appear to worsen GI tolerability. A 2023 analysis in Diabetes, Obesity and Metabolism (Frias et al.) found that patients who required dose reductions due to GI side effects had faster initial escalation histories. The clinical guidance from the American Gastroenterological Association also explicitly recommends slowing escalation if GI symptoms emerge.

Her claim that semaglutide caused more side effects because she went up "every four weeks" is plausible but not provable from her personal experience alone. The STEP trials for semaglutide used a 16-week escalation to 2.4 mg. Going faster than that likely does increase GI burden, but she can't separate the drug from the titration speed in her own n=1 case.

What did they get wrong (or right)?

Let's be honest about what she got right: a lot. The principle that slower titration reduces GI side effects is clinically sound and consistent with prescribing guidance. Her framing that one to two pounds per week at a steady dose is a success, not a failure, is accurate and genuinely useful pushback against the "more is better" mindset that gets people into trouble with these medications.

Where she gets sloppy is the implicit comparison between semaglutide and tirzepatide. She lost 52 pounds on semaglutide in 4.5 months and 47 pounds on tirzepatide in 5.5 months. She says results are "very similar," but she's comparing two different protocols, two different speeds, different life contexts, and a stated increase in muscle mass this time around. You can't cleanly conclude the drugs perform the same for her. She also doesn't acknowledge that tirzepatide is a dual GIP/GLP-1 agonist while semaglutide is a GLP-1 agonist only. That's a meaningful pharmacological difference that affects how these drugs work, and glossing over it misleads people who are trying to choose between them.

She also casually mentions staying at "5.5" mg, which is not a standard FDA-approved tirzepatide dose. Standard doses are 2.5, 5, 7.5, 10, 12.5, and 15 mg. This suggests she may be using a compounded product, which has a different regulatory and quality profile than brand-name tirzepatide. She never addresses that distinction.

What should you actually know?

A few things worth separating out from her personal story. First, slow titration is a real strategy with real support. If you're experiencing GI side effects, the answer is often to pause escalation, not push through. That's not just patient preference; it's consistent with clinical guidance.

Second, comparing two GLP-1 medications based on personal weight loss numbers without controlling for protocol, diet, exercise, or even which product you're using is not a valid comparison. It's a story, and stories have limits. The SURMOUNT-5 trial (2024) directly compared tirzepatide versus semaglutide and found tirzepatide produced greater weight loss on average, but individual results vary considerably.

Third, if you're using a compounded GLP-1 product, which her non-standard dose strongly implies, that product is not the same as FDA-approved Zepbound or Wegovy. Compounded drugs are not evaluated for safety and efficacy by the FDA. That doesn't mean they don't work, but it means the quality assurance framework is different. Any telehealth platform or provider should be transparent about this with patients.

Her advice to stop comparing your results to others and "be okay with it taking a little bit longer" is, frankly, some of the more grounded GLP-1 content on TikTok. The pressure to lose fast on these medications is real, and it drives poor decisions.